The new effort combines adaptive platform trial design, AI-enabled site activation, nationwide data infrastructure, and patient data contribution tools to reduce timelines, costs, and patient burden across clinical development.
|Articles|August 19, 2013
Woodley Announces the Appointment of Vijay Manchha
Woodley Equipment Company, a leading specialist medical and laboratory equipment supplier to the Clinical Trials industry has welcomed a new member to their Team.
Advertisement
Vijay has comprehensive experience of the Clinical Trials Industry having previously worked for VWR and Fisher Scientific. In these roles Vijay was responsible for managing and developing varied accounts from Research and Academia to Pharmaceutical and Biotech clients.
Vijay joins Woodley at a time of expansion and growth and will be responsible for developing new business within the company’s existing global markets. Vijay will further strengthen Woodley’s ability to offer turnkey solutions to the Clinical Trials Industry.
Woodley Equipment has been a trusted supplier of equipment solutions to the Clinical Trials industry for over 20 years. Woodley is the supplier of choice to many of the largest companies in Clinical Research, as well as the partner of small and medium sized companies around the World.
Advertisement
Related to this article
In this video interview, Claire Riches, VP of clinical solutions at Citeline, explains how AI is shifting trial risk management from reactive to proactive—enabling sponsors to pressure-test protocols and anticipate pivots before a single patient is enrolled.
In today's ACT Brief, we examine AI's role as trial design advisor with human leadership, how to govern autonomous agents in regulated operations, and real-world outcomes from switching to oral weight-loss therapy.
AI agents in clinical operations acquire broader autonomous capability through expanded permissions, tools, memory, and delegated authority, requiring governance focused on whether effective capability has shifted outside approved boundaries rather than whether software has changed.
In this video interview, Claire Riches, VP of clinical solutions at Citeline, makes the case for AI as a sophisticated strategic advisor in trial design while arguing that humans must remain in the lead—especially when factors the model can't fully account for are at stake.
In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the disconnect between FDA rulemaking and enforcement on compounded therapies.
RWE is finding a role earlier in drug development than ever before, but the data quality, integration, and organizational alignment required to make it regulatory-grade are still catching up to the ambition.
In this video interview, Claire Riches, VP of clinical solutions at Citeline, explains why combining analog trial performance data with real-world patient data and site-level recruitment history gives sponsors a far more honest picture of whether their enrollment assumptions are actually achievable.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
The Control Plane for Agentic Clinical Operations: Governing Autonomous Digital Actors in Regulated Trials
2
Where AI Leads in Trial Design—and Where Humans Still Need To
3
HHS Launches SURPASS Program and Three Complementary Initiatives to Transform Clinical Trial Design and Infrastructure
4
What an AI-Informed Approach Means for How Sponsors Think About Risk
5